

Patient's Reported Outcomes

Role in clinical development and approval decisions



Subjects



What is a Patient Reported Outcome?


Pro's and Con's

Requirements

Role in Decision making

Patient Reported Outcomes





PRO's are not rare, but are diverse



Examples:

Pain scale

Dyspepsia Symptom Severity Index

Fatigue Severity Scale (FSS)

Patient Global impression of change (PGI-C)


Multiple Sclerosis Walking scale (MSWS-12)

Crohn's Disease Activity Index

Parkinson Quality of Life (PDQL/PDQ-37

European Qol scale (EU-QOL-5D) Ect

Pain / MSW-12 / PGCI-C



PGI-C: Clinical Global Impression of Change

- 1 Very much improved
- 2 Much improved
- 3 Minimal improved
- 4 No change
- 5 Minimal worse
- 6 Much worse
- 7 Very much worse

Table S1 The 12-item Multiple Sclerosis Walking Scale (MSWS-12)

- These questions ask about limitations to your walking due to MS during the past 2 weeks.
- For each statement, please circle the one number that best describes your degree of limitation.
- Please answer all questions even if some seem rather similar to others, or seem irrelevant to you.
- If you cannot walk at all, please tick this box. \Box

In the past two weeks, how much has your MS	Not at all	A little	Moderately	Quite a bit	Extremely
I. Limited your ability to walk?		2	3	4	5
2. Limited your ability to run?		2	3	4	5
3. Limited your ability to climb up and down stairs?		2	3	4	5
4. Made standing when doing things more difficult?		2	3	4	5
5. Limited your balance when standing or walking?		2	3	4	5
6. Limited how far you are able to walk?		2	3	4	5
7. Increased the effort needed for you to walk?		2	3	4	5
8. Made it necessary for you to use support when walking indoors (eg, holding on to furniture, using a stick, etc.)?		2	3	4	5
9. Made it necessary for you to use support when walking outdoors (eg, using a stick, a frame, etc.)?		2	3	4	5
10. Slowed down your walking?		2	3	4	5
11. Affected how smoothly you walk?		2	3	4	5
12. Made you concentrate on your walking?		2	3	4	5

Please check that you have circled ONE number for EACH question

Note: Reprinted with permission from Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Neurology. 2003;60(1):3 I-36. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without the permission Souther (1) Start of the Burn the publisher Wolters Kluwer Health. Please contact healthpermissions@wolterskluwer.com for further information.

PDQL-HR 37 items



201/0010

This questionnaire has 37 questions, which will help us to know they are all answered. Place a tick $$ in the box that you fee		the state of the s			
How often in the last 3 months have you had trouble with	All the time	Most of the time	Som	ne of the time A little of the time No	CVC
 Stiffness? Feeling generally unwell? Feeling that you are no longer able to do your hobbies? Being tense? Feeling insecure of yourself due to your physical 	0		0000		son's Disease Quality of Life questionnaire tems, which provide an overall total score sub-scales
limitations? 6. Shaking of your hand(s)? 7. Feeling worn out or having no energy?	0		000	Sub-scale	Item numbers
8. Difficulties in doing sport or leisure activities? 9. Clumsiness? 10. Feeling embarrassed about your illness?				Parkinsonian symptoms (14 items) Systemic symptoms (7 items) Social functioning items (7 items) Emotional functioning (9 items)	1, 4, 6, 11, 14, 16, 20, 22, 25, 27, 30, 32, 3 2, 7, 13, 19, 24, 28, 33 3, 8, 12, 17, 23, 29, 37 5, 10, 15, 18, 21, 26, 31, 34, 37
				The responses to the items are scored scores are indicative of better quality of	d for the total score and the sub-scales. Higher

EuroQOL (EQ-5D-3L)

B **G** *M E B*

By placing a tick in one box in each group below, please indicate which statements best describe your own health state today.

Mobility

I have no problems in walking about	
I have some problems in walking about	
Lam confined to bed	

Self-Care

I have no problems with self-care	
I have some problems washing or dressing myself	
I am unable to wash or dress myself	

Usual Activities (e.g. work, study, housework, family or leisure activities)

I have no problems with performing my usual activities

I have some problems with performing my usual activities

I am unable to perform my usual activities

Pain/Discomfort

I have no pain or discomfort	
I have moderate pain or discomfort	
I have extreme pain or discomfort	

Anxiety/Depression

I am not anxious or depressed
I am moderately anxious or depressed
□
I am extremely anxious or depressed
□



imaginable

Best

imaginable health state

Pros'

Cons'



- Patient-centered
- Independent from physician
- Perceived Benefit
- What matters

- Subjective → Double blind studies
- Can be driven by one sign/symptom
- Not very sensitive to change
- Not always disease specific
- (HR) QoL not interchangeable
- High variability

Requirements



PRO are clinical outcome measurements and thus need to be validated

- Face validity
- Is the scale reliable
- Content Validity

Validation of a PRO is a research discipline

- Sensitive to change
- Can we determine which xx points change would be of clinical relevance
- Sensitive to detect a treatment effect



Example: Parkinson's disease

Non-PRO	PRO	HRQoL	QoL	Approval	PRO in labeling?
UPDRS	CGI-I	PDQL	EQ-QoL-5D		
+	+	+	+	Yes	PRO yes (HR)QoL case by case
+	+	+	-	Yes	Idem
+	+	-	-	Yes	PRO yes Qol not applicable
+	-	-	-	Yes	Not applicable
-	-	+	+	No!	Not applicable



- PROs are certainly being utilized to support claims made by Marketing Authorization holders in product assessment and for labeling
- Play essential role for the approval/refusal products
 - autoimmune conditions, respiratory conditions, pain, neurological conditions and psychiatric conditions.
- PRO Result blinding and randomized are more trustworthiness,
 - open-label studies also contribute to patient-care decision making

Conclusion: Overall, PRO integration into the assessment of the benefit-risk and approval/refusal of products is gradually increasing.





Internal study MEB by Nora Al-Mugoter

Mentioning of PRO's as primary/secondary endpoint in European Public Assessment reports of 149 new products assessed between 2018-2020.

EPAR - Benefit risk assessments

- Discussion
- Effect Table



SmPC PRO's in the labelling



Increasing influence in decision making

May affect patent-care decision making



Description	number
PROs utilized as primary and/pr secondary endpoints and/or	84 (56.4%)
contributed to benefit-risk, effect table and product labeling	
PROs utilized as a primary endpoint	11 (7.10%)
PROs utilized as a secondary endpoint	74 (49.66%)
PROs mentioned in the benefit-risk balance	55 (36.9%)
PROs mentioned in the Effect table	37 (25.0%)
PROs mentioned in the SmPC	41 (29.5%)

Type of treatment and PRO use/contribution

